Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isao Usui

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Journal of Inflammation (London, England)|August 28, 2009
Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathwayChikaaki Kobashi, Sachie Asamizu, Manabu Ishiki, et al.
Molecular Endocrinology (Baltimore, Md.)|July 5, 2005
G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytesIsao Usui, Takeshi Imamura, Jennie L Babendure, et al.
International Journal of Cardiology|February 8, 2021
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterolTeruo Jojima, Shintaro Sakurai, Sho Wakamatsu, et al.
Clinical Case Reports|October 22, 2020
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medicationYasutake Shinohara, Toshie Iijima, Shintaro Sakurai, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|July 13, 2026
Breakthrough drugs in the treatment of hypertension-related diseaseSatoshi Hoshide, Masaki Mogi, Shigeru Shibata, et al.
Endocrinology|May 30, 2013
Impact of divergent effects of astaxanthin on insulin signaling in L6 cellsManabu Ishiki, Yasuhiro Nishida, Hiroshi Ishibashi, et al.
Molecular and Cellular Biology|October 1, 2004
beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1Isao Usui, Takeshi Imamura, Jie Huang, et al.
International Journal of Clinical Practice|February 28, 2019
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver diseaseYoshimasa Aso, Kanako Kato, Shintaro Sakurai, et al.
Internal Medicine (Tokyo, Japan)|February 9, 2022
Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe ObesityToshimitsu Shinzawa, Isao Usui, Kanako Hanawa, et al.
International Journal of Molecular Sciences|October 27, 2019
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular CarcinomaTeruo Jojima, Sho Wakamatsu, Masato Kase, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Journal of Inflammation (London, England)|August 28, 2009
Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathwayChikaaki Kobashi, Sachie Asamizu, Manabu Ishiki, et al.
Molecular Endocrinology (Baltimore, Md.)|July 5, 2005
G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytesIsao Usui, Takeshi Imamura, Jennie L Babendure, et al.
International Journal of Cardiology|February 8, 2021
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterolTeruo Jojima, Shintaro Sakurai, Sho Wakamatsu, et al.
Clinical Case Reports|October 22, 2020
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medicationYasutake Shinohara, Toshie Iijima, Shintaro Sakurai, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|July 13, 2026
Breakthrough drugs in the treatment of hypertension-related diseaseSatoshi Hoshide, Masaki Mogi, Shigeru Shibata, et al.
Endocrinology|May 30, 2013
Impact of divergent effects of astaxanthin on insulin signaling in L6 cellsManabu Ishiki, Yasuhiro Nishida, Hiroshi Ishibashi, et al.
Molecular and Cellular Biology|October 1, 2004
beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1Isao Usui, Takeshi Imamura, Jie Huang, et al.
International Journal of Clinical Practice|February 28, 2019
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver diseaseYoshimasa Aso, Kanako Kato, Shintaro Sakurai, et al.
Internal Medicine (Tokyo, Japan)|February 9, 2022
Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe ObesityToshimitsu Shinzawa, Isao Usui, Kanako Hanawa, et al.
International Journal of Molecular Sciences|October 27, 2019
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular CarcinomaTeruo Jojima, Sho Wakamatsu, Masato Kase, et al.
Pageof 9